Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Introduced Apr 30, 2026 by Sen. Lisa Murkowski
The Senate passed it. The House has to pass it before it can reach the President.
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The bill reauthorizes
grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
Read the full summary on Congress.govSummary by the Congressional Research Service.
No recorded roll-call vote on this bill — it may have passed by voice vote or unanimous consent, which don't record individual votes.
- Aug 10, 2026Held at the desk.
- Aug 10, 2026Received in the House.
- Aug 10, 2026Message on Senate action sent to the House.
- Aug 4, 2026Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)
- Aug 4, 2026Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.
- Jul 16, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 461.
- Jul 16, 2026Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jun 17, 2026Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Apr 30, 2026Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Apr 30, 2026Introduced in Senate